Immunotherapy as a strategy for the treatment of non-small-cell lung cancer

Gregory Holt, Eckhard R. Podack, Luis E. Raez

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Positive modulation of a patient's immune system to produce antitumor immunity is an attractive strategy that may improve the dismal outcomes typically associated with non-small-cell lung cancer (NSCLC). Using methods that either augment specific antitumor immunity or positively influence the patient's immune system to allow the de novo generation of immunity to encompass current strategies used in recent clinical trials of NSCLC. Encouraging results of Phase II trials in antigen-specific immunotherapy have led to three subsequent Phase III trials, which are currently enrolling. Results of these trials will improve our understanding of the role that immunotherapy plays in the treatment of NSCLC. Successful application of a humoral vaccine in Cuba led to its approval for the treatment of advanced NSCLC patients in that country. To date, trials involving nonspecific immunotherapeutic interventions have failed to improve outcomes in NSCLC and may indicate a need to combine them with antigen-specific vaccines. Although these trials will greatly advance our knowledge of NSCLC immunotherapy, we believe truly efficacious immunotherapy may only result from implementation of strategies to both augment antitumor immunity and counteract tumor-mediated immunosuppression.

Original languageEnglish
Pages (from-to)43-54
Number of pages12
JournalTherapy
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Immunotherapy
Immunity
Immune System
Therapeutics
Vaccines
Antigens
Cuba
Immunosuppression
Clinical Trials
Neoplasms

Keywords

  • allogenic tumor cell vaccines
  • CpG oligonucleotides
  • EGF
  • immunotherapy
  • lung cancer vaccine
  • MAGE-A3
  • MUC1
  • ONTAK

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. / Holt, Gregory; Podack, Eckhard R.; Raez, Luis E.

In: Therapy, Vol. 8, No. 1, 01.01.2011, p. 43-54.

Research output: Contribution to journalArticle

Holt, Gregory ; Podack, Eckhard R. ; Raez, Luis E. / Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. In: Therapy. 2011 ; Vol. 8, No. 1. pp. 43-54.
@article{37a25c18541844898eabb02a243e7a3f,
title = "Immunotherapy as a strategy for the treatment of non-small-cell lung cancer",
abstract = "Positive modulation of a patient's immune system to produce antitumor immunity is an attractive strategy that may improve the dismal outcomes typically associated with non-small-cell lung cancer (NSCLC). Using methods that either augment specific antitumor immunity or positively influence the patient's immune system to allow the de novo generation of immunity to encompass current strategies used in recent clinical trials of NSCLC. Encouraging results of Phase II trials in antigen-specific immunotherapy have led to three subsequent Phase III trials, which are currently enrolling. Results of these trials will improve our understanding of the role that immunotherapy plays in the treatment of NSCLC. Successful application of a humoral vaccine in Cuba led to its approval for the treatment of advanced NSCLC patients in that country. To date, trials involving nonspecific immunotherapeutic interventions have failed to improve outcomes in NSCLC and may indicate a need to combine them with antigen-specific vaccines. Although these trials will greatly advance our knowledge of NSCLC immunotherapy, we believe truly efficacious immunotherapy may only result from implementation of strategies to both augment antitumor immunity and counteract tumor-mediated immunosuppression.",
keywords = "allogenic tumor cell vaccines, CpG oligonucleotides, EGF, immunotherapy, lung cancer vaccine, MAGE-A3, MUC1, ONTAK",
author = "Gregory Holt and Podack, {Eckhard R.} and Raez, {Luis E.}",
year = "2011",
month = "1",
day = "1",
doi = "10.2217/thy.10.84",
language = "English",
volume = "8",
pages = "43--54",
journal = "Therapy",
issn = "2044-9038",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Immunotherapy as a strategy for the treatment of non-small-cell lung cancer

AU - Holt, Gregory

AU - Podack, Eckhard R.

AU - Raez, Luis E.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Positive modulation of a patient's immune system to produce antitumor immunity is an attractive strategy that may improve the dismal outcomes typically associated with non-small-cell lung cancer (NSCLC). Using methods that either augment specific antitumor immunity or positively influence the patient's immune system to allow the de novo generation of immunity to encompass current strategies used in recent clinical trials of NSCLC. Encouraging results of Phase II trials in antigen-specific immunotherapy have led to three subsequent Phase III trials, which are currently enrolling. Results of these trials will improve our understanding of the role that immunotherapy plays in the treatment of NSCLC. Successful application of a humoral vaccine in Cuba led to its approval for the treatment of advanced NSCLC patients in that country. To date, trials involving nonspecific immunotherapeutic interventions have failed to improve outcomes in NSCLC and may indicate a need to combine them with antigen-specific vaccines. Although these trials will greatly advance our knowledge of NSCLC immunotherapy, we believe truly efficacious immunotherapy may only result from implementation of strategies to both augment antitumor immunity and counteract tumor-mediated immunosuppression.

AB - Positive modulation of a patient's immune system to produce antitumor immunity is an attractive strategy that may improve the dismal outcomes typically associated with non-small-cell lung cancer (NSCLC). Using methods that either augment specific antitumor immunity or positively influence the patient's immune system to allow the de novo generation of immunity to encompass current strategies used in recent clinical trials of NSCLC. Encouraging results of Phase II trials in antigen-specific immunotherapy have led to three subsequent Phase III trials, which are currently enrolling. Results of these trials will improve our understanding of the role that immunotherapy plays in the treatment of NSCLC. Successful application of a humoral vaccine in Cuba led to its approval for the treatment of advanced NSCLC patients in that country. To date, trials involving nonspecific immunotherapeutic interventions have failed to improve outcomes in NSCLC and may indicate a need to combine them with antigen-specific vaccines. Although these trials will greatly advance our knowledge of NSCLC immunotherapy, we believe truly efficacious immunotherapy may only result from implementation of strategies to both augment antitumor immunity and counteract tumor-mediated immunosuppression.

KW - allogenic tumor cell vaccines

KW - CpG oligonucleotides

KW - EGF

KW - immunotherapy

KW - lung cancer vaccine

KW - MAGE-A3

KW - MUC1

KW - ONTAK

UR - http://www.scopus.com/inward/record.url?scp=78650929413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650929413&partnerID=8YFLogxK

U2 - 10.2217/thy.10.84

DO - 10.2217/thy.10.84

M3 - Article

AN - SCOPUS:78650929413

VL - 8

SP - 43

EP - 54

JO - Therapy

JF - Therapy

SN - 2044-9038

IS - 1

ER -